{"id":112400,"date":"2026-09-09T11:42:26","date_gmt":"2026-09-09T09:42:26","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/orikine-appoints-new-ceo-and-leadership-team-to-advance-ork1-in-autoimmune-disease\/"},"modified":"2026-09-10T15:33:28","modified_gmt":"2026-09-10T13:33:28","slug":"orikine-appoints-new-ceo-and-leadership-team-to-advance-ork1-in-autoimmune-disease","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/orikine-appoints-new-ceo-and-leadership-team-to-advance-ork1-in-autoimmune-disease\/","title":{"rendered":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease"},"content":{"rendered":"

Orikine Bio<\/a>, a pioneering biotechnology company developing biospecific cytokines to reprogram the immune system and treat autoimmune diseases and chronic inflammatory conditions, based at the Barcelona Science Park (PCB-UB), has announced changes to its executive team to support the next stage of its corporate development.<\/strong><\/p>\n

Sabrina Kuttruff-Coqui<\/strong>, Ph.D., has been appointed Chief Executive Officer, and Joachim Koch<\/strong>, Ph.D., has been appointed Chief Scientific Officer and Chief Development Officer. Both bring decades of biotechnology industry experience to accelerate Orikine’s growth strategy and advance Orikine’s pipeline. Andreas Muehler<\/strong>, MD, MBA, joins as part-time Chief Medical Officer, bringing a strong medical track record for the transition of lead candidate ORK1 toward an IND submission and first-in-human studies. Pilar Casado Garc\u00eda<\/strong> will continue to serve as Chief Financial Officer, ensuring financial and institutional continuity.<\/p>\n

The Orikine team is expanding at a critical inflection point, as ORK1 advances from preclinical research to IND-enabling studies in inflammatory bowel disease.<\/p>\n

\u201cTransitioning toward first-in-human studies requires leadership with deep experience in translating innovative science into clinical programs and building the operational foundation required for long-term growth. Our expanded leadership team has been carefully selected to guide Orikine through this key phase of its development. I am confident in the team\u2019s ability to build on the company\u2019s progress while remaining focused on our vision of improving the lives of people affected by autoimmune disease,\u201d said Larry Edwards<\/strong>, Chair of Orikine\u2019s Board of Directors. \u201cOn behalf of the Board, I would also like to sincerely thank Christian Pangratz<\/strong> for his dedication to Orikine and the integral part he played in establishing the company’s foundation. We wish him all the best for his next endeavors\u201d, added.<\/p>\n

\u201cOrikine is at a pivotal moment, transitioning from a research-driven organization into a company built to deliver toward the clinical potential of its pipeline. The depth of experience provided by our expanded leadership team makes us well positioned to advance ORK1 toward the clinic and enables the company\u2019s next phase of growth, including future financing and partnership opportunities,\u201d added Sabrina Kuttruff-Coqui<\/strong>, new CEO at the company. \u201cI am impressed with Orikine\u2019s differentiated approach to restoring self-reactive immunity, which has the potential to transform the treatment of autoimmune disease and provide durable benefits for patients\u201d, explains.<\/p>\n

The lead candidate ORK1 is a bi-functional cytokine biologic designed to act as a myeloid switch. Through the simultaneous activation of the CSF1 and IL-10 pathways, ORK1 drives myeloid cells into regulatory macrophages that migrate to inflamed tissue and restore immune homeostasis and reverse the root cause of autoimmune disease. In preclinical studies, ORK1 has been shown to selectively engage with circulating monocytes and induce durable reprogramming. Moreover, in two independent in vivo models, a single application of ORK1 strongly reduced ulcerative colitis symptoms.<\/p>\n

\u201cDual cytokine targeting represents a compelling opportunity to change how we treat inflammatory bowel disease and other autoimmune diseases at their source. In parallel to advancing ORK1 towards the clinic, I am committed to strengthening our platform\u2019s capabilities and expanding our pipeline to develop novel therapeutic candidates for a broad range of autoimmune diseases. I’m looking forward to working alongside this team to translate strong preclinical science into a clinical-stage pipeline of disease-modifying candidates,\u201d said Joachim Koch<\/strong>, Chief Scientific and Development Officer at Orikine.<\/p>\n

Sabrina Kuttruff-Coqui<\/strong> brings a proven track record in biopharma transactions, NASDAQ listings, and company transformations from R&D to fully integrated biopharmaceutical companies. She joins Orikine after serving as Chief Financial Officer of Aicuris through its $920M acquisition by Asahi Kasei, and holding several leadership positions at Immatics, where she played a key role in the company’s NASDAQ listing \u2014 bringing with her an extensive scientific background and biotech leadership experience.<\/p>\n

Joachim Koch<\/strong> brings more than 25 years of life sciences experience across academia and the biotechnology industry. Before joining Orikine, he served as Vice President and Head of Discovery, Research and Translational Immunology at Affimed, where he helped define the scientific strategy and supported multiple IND applications. At Orikine, he will apply his deep scientific and development expertise to advance the company\u2019s pipeline including ORK1 as well as maximizing the potential of its proprietary Foldikine\u2122 platform by further enhancing its capabilities and creating novel immune switches.<\/p>\n

Andreas Muehler<\/strong> is a seasoned life sciences executive with over 30 years of leadership experience across biotech and pharma in both private and public companies in the U.S. and Europe. His expertise spans all stages of the product lifecycle, including clinical development, regulatory strategy, product launches and business development with a particular focus on autoimmune and inflammatory diseases. Most recently, he served as Chief Medical Officer of Immunic, a clinical-stage biotech developing therapies for autoimmune diseases, where he helped guide the company through preclinical and clinical development of several investigational medicines, and supported its NASDAQ listing and investor interactions.<\/p>\n

\u00bb Link to the news: <\/strong>Orikine’s website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orikine Bio, a pioneering biotechnology company developing biospecific cytokines to reprogram the immune system and treat autoimmune diseases and chronic inflammatory conditions, based at the Barcelona Science Park (PCB-UB), has…<\/p>\n","protected":false},"author":14,"featured_media":112393,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[375],"class_list":["post-112400","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-orikine"],"acf":[],"yoast_head":"\nOrikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-09T09:42:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-10T13:33:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease\",\"datePublished\":\"2026-09-09T09:42:26+00:00\",\"dateModified\":\"2026-09-10T13:33:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/\"},\"wordCount\":822,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/orikine-ceo-900x330-px-25.png\",\"keywords\":[\"Orikine\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/\",\"name\":\"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/orikine-ceo-900x330-px-25.png\",\"datePublished\":\"2026-09-09T09:42:26+00:00\",\"dateModified\":\"2026-09-10T13:33:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/orikine-ceo-900x330-px-25.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/orikine-ceo-900x330-px-25.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona","description":"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/","og_locale":"en_US","og_type":"article","og_title":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona","og_description":"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.","og_url":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-09-09T09:42:26+00:00","article_modified_time":"2026-09-10T13:33:28+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png","type":"image\/png"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease","datePublished":"2026-09-09T09:42:26+00:00","dateModified":"2026-09-10T13:33:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/"},"wordCount":822,"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png","keywords":["Orikine"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/","url":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/","name":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png","datePublished":"2026-09-09T09:42:26+00:00","dateModified":"2026-09-10T13:33:28+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"Sabrina Kuttruff-Coqui has been appointed CEO, Joachim Koch is the new CSO and CDO. Andreas Muehler joins the company as medical director.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/orikine-ceo-900x330-px-25.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/orikine-nomena-una-nova-ceo-i-un-nou-equip-directiu-per-impulsar-ork1-en-malalties-autoimmunitaries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=112400"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112400\/revisions"}],"predecessor-version":[{"id":112404,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112400\/revisions\/112404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/112393"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=112400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=112400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=112400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}